Opdivo (Nivolumab) vs Zynlonta (loncastuximab tesirine-lpyl)

Opdivo (nivolumab) is an immune checkpoint inhibitor that works by blocking the PD-1 pathway, which enhances the body's immune response against cancer cells, and is commonly used for a variety of cancers including melanoma, lung cancer, and kidney cancer. Zynlonta (loncastuximab tesirine-lpyl) is an antibody-drug conjugate specifically targeting CD19, a protein expressed on the surface of certain types of B-cell lymphomas, and is used for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). When deciding between Opdivo and Zynlonta, it is essential to consider the type of cancer being treated, as Opdivo is used for a broader range of cancers, while Zynlonta is specialized for certain B-cell lymphomas, and the decision should be made in consultation with an oncologist who can evaluate the specific medical history and cancer characteristics.

Difference between Opdivo and Zynlonta

Metric	Opdivo (Nivolumab)	Zynlonta (loncastuximab tesirine-lpyl)
Generic name	Nivolumab	Loncastuximab tesirine-lpyl
Indications	Unresectable or metastatic melanoma, metastatic non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, gastric cancer, gastroesophageal junction cancer, and malignant pleural mesothelioma	Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Mechanism of action	Programmed death receptor-1 (PD-1) blocking antibody	Antibody-drug conjugate targeting CD19
Brand names	Opdivo	Zynlonta
Administrative route	Intravenous infusion	Intravenous infusion
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, decreased appetite, and constipation	Thrombocytopenia, neutropenia, anemia, fatigue, musculoskeletal pain, edema, nausea, and fever
Contraindications	Hypersensitivity to nivolumab or any of its excipients	Hypersensitivity to loncastuximab tesirine-lpyl or any of its excipients
Drug class	Immune checkpoint inhibitor	Antibody-drug conjugate
Manufacturer	Bristol Myers Squibb	ADC Therapeutics

Efficacy

Opdivo (Nivolumab) Efficacy in Lymphoma

Opdivo, also known by its generic name Nivolumab, is an immunotherapy drug that has been studied for its efficacy in treating certain types of lymphoma. It is a programmed death receptor-1 (PD-1) blocking antibody that has shown promise in the treatment of classical Hodgkin Lymphoma (cHL), particularly after the failure of autologous stem cell transplant (ASCT) or after at least two types of treatment in patients who are not ASCT candidates. Clinical trials have demonstrated that Opdivo can induce a significant response rate in patients with relapsed or refractory cHL, leading to its approval by regulatory agencies for this indication.

While the efficacy of Opdivo in non-Hodgkin lymphoma (NHL) is still under investigation, some studies suggest that it may provide benefits to patients with certain subtypes of NHL. The response rates in these studies vary depending on the subtype and the prior treatments the patients have received. However, it is important to note that the use of Opdivo for NHL may still be considered off-label, and its efficacy in this broader group of lymphoma patients requires further validation through clinical trials.

Zynlonta (Loncastuximab Tesirine-lpyl) Efficacy in Lymphoma

Zynlonta, with the generic name loncastuximab tesirine-lpyl, is a CD19-directed antibody and alkylating agent conjugate used for the treatment of certain types of B-cell lymphomas. It has shown efficacy in adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low-grade lymphoma, and other high-grade B-cell lymphomas. Clinical trials have demonstrated that Zynlonta can achieve objective response rates in a significant proportion of patients, with a subset achieving complete responses.

The approval of Zynlonta for these indications was based on the results of a multicenter, open-label, single-arm trial, where patients showed a marked response to the treatment. As a targeted therapy, Zynlonta represents a novel approach in the management of refractory or relapsed B-cell lymphomas, offering a new option for patients who have exhausted other treatment lines. Nevertheless, ongoing studies continue to evaluate its long-term efficacy and safety profile in a broader population of lymphoma patients.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Zynlonta

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Opdivo or Zynlonta today

If Opdivo or Zynlonta are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Zynlonta

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: